南京海辰药业股份有限公司 二、独立董事年度履职概况 （一）出席董事会及股东大会情况 报告期内，公司共召开 6 次董事会会议和 1 次股东大会，我亲自出席 3 次董 在董事会会议召开前我认真阅读公司提供的相关材料，研究决策事项，了解 公司经营和运作情况，为参与公司重要决策做好充分准备。会上，我认真审议各 项议题，积极参与讨论并提出合理化建议，并就其中有关事项发表独立意见，认 真行使表决权，为公司董事会作出正确决策起了积极的作用。2023 年，我对提交 董事会的全部议案经认真审议，均投出赞成票，没有反对、弃权的情形。同时， 公司对于我的工作也给予了极大支持，没有妨碍独立董事做出独立判断的情况发 生。 2023 年度独立董事述职报告 （周浩） 各位股东及股东代表： 本人（周浩）作为南京海辰药业股份有限公司（以下简称"公司"）的独立 董事，严格按照《公司法》《证券法》《上市公司独立董事管理办法》《上市公 司自律监管指引第 2 号——创业板上市公司规范运作》以及《公司章程》《独立 董事工作制度》等相关法律、法规、规章的规定和要求，在 2023 年度工作中， 诚实、勤勉、独立地履行职责，积极出席相关会议，认真审议董事会各 ...

证券代码：300584 证券简称：海辰药业 公告编号：2024-008 南京海辰药业股份有限公司 第四届监事会第十二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、本次监事会由监事会主席罗艳女士召集，会议通知于 2024 年 4 月 14 日 通过电话、电子邮件、专人送达等形式送达至各位监事，监事会会议通知中包括 会议的相关材料，同时列明了会议的召开时间、地点、内容和方式。 2、本次监事会于 2024 年 4 月 24 日在公司会议中心三楼会议室召开，本次 会议采取现场表决的方式召开。 3、本次监事会应出席 3 人，实际出席 3 人，全部以现场表决的方式参会。 4、本次监事会由监事会主席罗艳女士主持。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《公司章程》的有关规定。 二、监事会会议审议情况 会议审议并通过如下议案： 1、审议通过了《2023 年度监事会工作报告》 具体内容详见公司同日披露在中国证监会创业板指定信息披露网站巨潮资 讯网（www.cninfo.com.cn）的《2023 ...

南京海辰药业股份有限公司 董事会审计委员会对年审会计师履行监督职责情况报告 名称：天衡会计师事务所（特殊普通合伙） 机构性质：特殊普通合伙企业 南京海辰药业股份有限公司（以下简称"公司"）董事会审计委员会根据《中 华人民共和国公司法》《上市公司治理准则》《国有企业、上市公司选聘会计师 事务所管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等法律法规、规范性文件以及《公司章程》《董事会审计委员 会工作细则》等规定和要求，本着勤勉尽责的原则，恪尽职守，认真履职。现将 董事会审计委员会对会计师事务所履行监督职责的情况汇报如下： 一、会计师事务所基本信息 （一）机构信息 1、基本信息 3、业务信息 2023 年经审计的收入总额：61,472.84 万元 成立日期：2013 年 11 月 4 日 统一社会信用代码：913200000831585821 注册地址：江苏省南京市建邺区江东中路 106 号 1907 室 首席合伙人：郭澳 2、人员信息 2023 年末合伙人数量：85 人 2023 年末注册会计师数量：419 人 2023 年末签署过证券业务审计报告的注册会计师人数：222 ...

证券代码：300584 证券简称：海辰药业 公告编号：2024-009 南京海辰药业股份有限公司 关于续聘 2024 年度审计机构的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 南京海辰药业股份有限公司（以下简称"公司"）于2024年4月24日召开 了第四届董事会第十二次会议、第四届监事会第十二次会议，分别审议通过 了《关于续聘2024年度审计机构的议案》，同意续聘天衡会计师事务所（特殊 普通合伙）（以下简称"天衡"）为公司2024年度审计机构，并提交公司2023 年度股东大会审议。现就相关事项公告如下： 一、拟续聘会计师事务所事项的信息 （一）机构信息 1、基本信息 名称：天衡会计师事务所（特殊普通合伙） 机构性质：特殊普通合伙企业 成立日期：2013 年 11 月 4 日 统一社会信用代码：913200000831585821 注册地址：江苏省南京市建邺区江东中路 106 号 1907 室 首席合伙人：郭澳 2、人员信息 2023 年末合伙人数量：85 人 2023 年末注册会计师数量：419 人 2023 年末签署过证券业务审计报告的注册会计师人 ...

证券代码：300584 证券简称：海辰药业 公告编号：2024-013 南京海辰药业股份有限公司 关于计提资产减值准备的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次计提资产减值准备概述 根据《深圳证券交易所创业板股票上市规则》《企业会计准则第 8 号—资 产减值》及公司会计政策等相关规定的要求，基于谨慎性原则，为了更加真 实、准确地反映公司截至 2023 年 12 月 31 日的资产状况和财务状况，公司对 2023 年度各类应收账款、应收款项融资、其他应收款、存货、固定资产、在建 工程、无形资产等资产进行了全面清查，对可能发生资产减值损失的资产计提 资产减值准备，具体情况如下： 二、计提资产减值准备的具体说明 1、应收款项 根据《企业会计准则》和公司相关会计政策，公司对应收款项的预期信用 损失进行评估，本年对应收账款计提坏账准备 165.19 万元；本年对其他应收款 计提坏账准备 2.51 万元。 2、存货跌价准备在资产负债表日，存货按照成本与可变现净值孰低计量。 当其可变现净值低于成本时，提取存货跌价准备。公司计提存货跌价准备后， 如果以前 ...

Revenue and Profit - The company's revenue for Q1 2024 was ¥104,561,855.22, a decrease of 10.78% compared to ¥117,201,090.18 in the same period last year[5] - Net profit attributable to shareholders increased by 9.37% to ¥13,357,813.44 from ¥12,213,813.89 year-on-year[5] - The company achieved operating revenue of CNY 104,561,855.22, a year-on-year decrease of 10.78%[12] - Net profit attributable to the listed company was CNY 13,357,813.44, an increase of 9.37% year-on-year[12] - Net profit for Q1 2024 reached CNY 13,357,813.44, an increase of 9.4% from CNY 12,213,813.89 in Q1 2023[19] Earnings Per Share - Basic and diluted earnings per share rose by 9.33% to ¥0.1113 from ¥0.1018 in the same period last year[5] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.1113, compared to CNY 0.1018 in Q1 2023[20] Cash Flow - The net cash flow from operating activities significantly dropped by 84.14%, amounting to ¥4,680,974.46 compared to ¥29,506,108.77 in the previous year[5] - The net cash flow from operating activities for the current period is ¥4,680,974.46, a decrease of 84.2% compared to ¥29,506,108.77 in the previous period[23] - Cash inflow from operating activities totaled ¥110,901,566.65, down 21.5% from ¥141,311,878.19 in the previous period[23] - Cash outflow from operating activities was ¥106,220,592.19, a decrease of 5.0% compared to ¥111,805,769.42 in the previous period[23] - The net cash flow from investing activities is -¥29,319,647.03, an improvement from -¥53,605,687.16 in the previous period[23] - Cash inflow from financing activities was ¥30,000,000.00, down 38.8% from ¥49,000,000.00 in the previous period[23] - The net cash flow from financing activities is -¥2,302,894.43, a significant decline compared to ¥21,493,951.38 in the previous period[23] - The ending balance of cash and cash equivalents is ¥19,874,244.44, a decrease from ¥92,465,697.80 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,411,909,020.32, reflecting a slight increase of 0.22% from ¥1,408,864,380.40 at the end of the previous year[5] - Total liabilities decreased to CNY 411,047,921.63 from CNY 421,368,242.18 year-over-year[16] - Non-current assets totaled CNY 1,058,467,056.30, an increase from CNY 1,031,568,551.09 in Q1 2023[16] Research and Development - Research and development expenses surged by 80.20% to ¥5,429,812.44, indicating increased investment in innovation[8] - Research and development expenses increased to CNY 5,429,812.44, up 80.5% from CNY 3,013,143.82 in the previous year[19] Sales Performance - Sales of the main product, rivaroxaban tablets, increased by 56.32% in volume and 53.88% in sales amount compared to the same period last year[14] - Sales of the injection of landiolol hydrochloride reached CNY 6,075,000, with a volume increase of 28.46% year-on-year[14] - The company reported a significant increase in sales of cefmetazole injection, with a volume increase of 6680.00% year-on-year[14] Shareholder Information - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, while the second-largest shareholder, Ms. Jiang Xiaoqin, holds 9.98%[10] Other Financial Metrics - The weighted average return on equity slightly improved to 1.34% from 1.28% year-on-year[5] - The company recorded a total of ¥39,253.47 in government subsidies related to its normal business operations[6] - Total operating costs for Q1 2024 were CNY 85,582,384.45, down 16.2% from CNY 102,187,516.82 in the same period last year[18] - Inventory as of the end of Q1 2024 was CNY 87,529,909.40, an increase from CNY 81,455,425.23 at the end of Q1 2023[16] - Accounts receivable stood at CNY 200,965,069.16, slightly down from CNY 206,779,467.11 at the beginning of the period[14] Employee and Tax Expenses - The company paid ¥24,165,067.57 in employee compensation, an increase of 5.7% from ¥21,925,357.04 in the previous period[23] - The company incurred tax payments of ¥17,967,780.68, up 21.4% from ¥14,841,281.98 in the previous period[23] - The company reported a cash outflow of ¥41,888,347.37 related to other operating activities, a decrease of 29.7% from ¥59,527,108.18 in the previous period[23] Strategic Focus - The company is focusing on refining sales management and adjusting product structure to improve performance[12] - Sales expenses decreased by 35.36% to ¥38,595,773.27, attributed to optimized sales strategies and improved sales personnel efficiency[8]

Financial Performance - The company's operating revenue for 2023 was ¥517,832,192, a decrease of 1.64% compared to ¥526,465,340 in 2022[19] - The net profit attributable to shareholders for 2023 was ¥36,315,554, an increase of 11.92% from ¥32,448,867 in 2022[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,965,334, reflecting a 17.51% increase from ¥31,458,351 in 2022[19] - The net cash flow from operating activities improved significantly to ¥23,932,692, a 511.26% increase from a negative cash flow of ¥5,819,338 in 2022[19] - The total assets at the end of 2023 were ¥1,408,864,380.40, an increase of 8.88% from ¥1,293,945,410.29 at the end of 2022[19] - The net assets attributable to shareholders increased to ¥987,496,138.22, up 3.89% from ¥950,566,396.43 at the end of 2022[19] - The basic earnings per share for 2023 were ¥0.3026, an increase of 11.91% compared to ¥0.2704 in 2022[19] - The diluted earnings per share also stood at ¥0.3026, reflecting the same growth of 11.91% from the previous year[19] - The weighted average return on equity for 2023 was 3.75%, an increase from 3.42% in 2022[19] Market and Product Development - The company plans to continue focusing on new product development and market expansion strategies to enhance future growth prospects[3] - The company has launched multiple high-quality products with significant market shares, including an injectable form of Torasemide, which achieved a market share of approximately 80% in its category[35] - The injectable form of Labetalol is a unique first-to-market product with two core patents, recommended in multiple clinical guidelines, and has been continuously included in the National Medical Insurance Directory[38] - Rivaroxaban tablets, the first oral direct Factor Xa inhibitor, have been included in several authoritative treatment guidelines and won bids in the national centralized procurement, enhancing the product's market competitiveness[39] - Tigecycline injection, known as a "super antibiotic," is included in the National Medical Insurance Directory and has been selected in the national centralized procurement, which is expected to increase its market share[40] - The injectable form of Torasemide is a new generation diuretic with strong and rapid effects, but its sales have been impacted by low-priced competitors in certain markets[41] - The company has established a comprehensive procurement, production, and sales system to ensure product quality and stable supply[42] - The company employs a sales model that emphasizes refined management and tracking of sales processes in hospitals to enhance market penetration[43] Research and Development - The company has established a comprehensive R&D system with over 60 dedicated personnel, focusing on drug development and innovation[45] - The company is actively involved in national and provincial-level technology projects, enhancing its R&D capabilities through collaboration with NMS Group, a leading European oncology drug research institution[46] - The company has submitted 3 invention patent applications and received authorization for 1 invention patent during the reporting period[57] - A total of 4 products (6 specifications) were approved for market by the National Medical Products Administration, including 4 generic products and 2 consistency evaluation products[57] - The company has 17 key research projects underway, with plans to submit several generic drug registration applications in 2024[60][61] Financial Management and Cost Control - The company achieved a production cost control and improved inventory efficiency, contributing to overall cost reduction[62] - The company reported a decrease in raw material costs by 29.79% to ¥43,526,694.72, contributing to improved margins[75] - The total sales expenses decreased by 10.09% to ¥241,595,638.54, reflecting cost control measures[80] - The company experienced a significant increase in depreciation expenses, which fell by 37.42% to ¥9,968,322.52[75] - The company’s investment activities generated a net cash outflow of ¥137,266,120.14, a decrease of 571.42% year-on-year[84] Corporate Governance - The company has established a comprehensive governance structure to ensure effective decision-making and protect shareholder rights[112] - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[115] - The board of directors includes a strategic committee, audit committee, nomination committee, and compensation and assessment committee to enhance governance[113] - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, linking their compensation to company performance and individual achievements[114] - The company has a complete research, production, and sales system, ensuring independent business operations[115] Environmental Responsibility - The company adheres to environmental regulations and has established a comprehensive environmental management system, meeting various national and local standards for wastewater and air emissions[164] - The company obtained an environmental protection administrative permit for wastewater discharge, valid from September 1, 2022, to August 31, 2027[164] - The company has implemented a comprehensive waste gas treatment system to manage emissions from various production processes, ensuring compliance with local environmental standards[169] - The company has established protocols for the management of hazardous waste, ensuring safe handling and disposal in accordance with environmental regulations[170] - The company invested 3.5683 million yuan in environmental governance and protection during the reporting period[174] Community Engagement - The company donated a total of 500,000 RMB worth of materials to the Hai Chen Hope Primary School during the Children's Day event[180] - Cumulative donations reached 690,000 RMB through participation in charity events in Jiangsu Province over the past three years[180] - The company provided over 490,000 RMB in various forms of assistance, benefiting 442 individuals during the reporting period[180]

南京海辰药业股份有限公司 2023 年度财务决算报告 一、2023 年度公司财务报告的审计情况 南京海辰药业股份有限公司（以下简称："公司"）编制的 2023 年财务报表已 经天衡会计师事务所（特殊普通合伙）审计，并出具了标准无保留意见的审计报告 （天衡审字(2024)00493 号），现将公司2023 年度的财务决算情况报告如下： 二、主要财务数据和指标 | 单位：万元 | | --- | | 项目 | 2023 年 | 2022 年 | 本年比上年 | | --- | --- | --- | --- | | | | | 增减 | | 营业收入 | 51,783.22 | 52,646.53 | -1.64% | | 归属于上市公司股东的净利润 | 3,631.56 | 3,244.89 | 11.92% | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 3,696.53 | 3,145.84 | 17.51% | | 经营活动产生的现金流量净额 | 2,393.27 | -581.93 | 511.26% | | 基本每股收益（元/股） | 0.3026 | 0.2704 | 11.91% | ...

2023 年正值公司成立二十周年，面对行业竞争加剧、市场信心不足等诸多不利因 素影响，全体员工在董事会和管理层的带领下，扎实推进降本增效，持续投入药品研 发，不断丰富业务板块，始终坚持高质量发展。报告期内公司实现营业收入 5.18 亿 元，同比下降 1.64%；归属于上市公司股东的净利润 3,631.56 万元，同比上升 11.92%，归属于上市公司股东的扣除非经常性损益的净利润 3,696.53 万元，同比上升 17.51%。2023 年，公司各项重点工作完成情况如下： （1）积极落实营销部署，深化重点品种终端覆盖。 2023 年，公司营销系统围绕年度推广目标，致力于提升重点品种注射用盐酸兰地 洛尔、利伐沙班片、注射用替加环素等的终端覆盖。报告期内，注射用盐酸兰地洛尔 于 2023 年底以简易续约方式再次被纳入国家医保目录，入选《国家心力衰竭指南》 （2023 版），被列为急性心衰发作患者的心室率控制推荐用药；公司持续深入推进该 品种医院开发工作，通过专业化的学术推广，已成功开发约 650 家三级医院、约 270 家二级医院，较上年新增约 170 家医院，实现销量翻倍。利伐沙班片 15mg 和 20mg 作 ...

南京海辰药业股份有限公司 在执行审计工作的过程中，天衡就会计师事务所和相关审计人员的独立性、 天衡会计师事务所（特殊普通合伙）（以下简称"天衡"）成立于 2013 年， 注册地址在江苏省南京市建邺区江东中路 106 号 1907 室，首席合伙人为郭澳。 截至 2023 年 12 月 31 日合伙人 85 人，注册会计师 419 人，签署过证券业务审计 报告的注册会计师 222 人。2023 年度业务总收入 61,472.84 万元、审计业务收 入 55,444.33 万元、证券业务收入 16,062.01 万元。 （二）聘任会计师事务所履行的程序 第四届董事会第七次会议及 2022 年年度股东大会审议通过了《关于续聘 2023 年度审计机构的议案》，同意续聘天衡会计师事务所（特殊普通合伙）为公 司 2023 年度财务审计机构，聘期一年。公司独立董事就该议案发表了事前认可 意见及同意的独立意见。 二、2023 年年审会计师事务所履职情况 按照《审计业务约定书》，遵循《中国注册会计师审计准则》和其他执业规 范，以及公司 2023 年年报工作安排，天衡对公司 2023 年度财务报告进行了审 计，同时对公司非经营性资 ...